Voya Investment Management LLC raised its holdings in Cambrex Co. (NYSE:CBM) by 7.1% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 32,674 shares of the biotechnology company’s stock after acquiring an additional 2,155 shares during the quarter. Voya Investment Management LLC owned approximately 0.10% of Cambrex worth $1,952,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also recently bought and sold shares of CBM. First Trust Advisors LP purchased a new stake in shares of Cambrex during the 1st quarter worth $1,154,000. UBS Asset Management Americas Inc. lifted its stake in shares of Cambrex by 56.7% during the 1st quarter. UBS Asset Management Americas Inc. now owns 19,438 shares of the biotechnology company’s stock worth $1,070,000 after purchasing an additional 7,035 shares during the last quarter. Karp Capital Management Corp purchased a new stake in shares of Cambrex during the 1st quarter worth $525,000. Parametric Portfolio Associates LLC raised its stake in Cambrex by 6.7% in the first quarter. Parametric Portfolio Associates LLC now owns 88,976 shares of the biotechnology company’s stock valued at $4,898,000 after buying an additional 5,624 shares during the last quarter. Finally, Ameritas Investment Partners Inc. purchased a new stake in Cambrex in the first quarter valued at about $151,000.
COPYRIGHT VIOLATION WARNING: This news story was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2017/10/28/voya-investment-management-llc-raises-position-in-cambrex-corporation-cbm.html.
Cambrex Co. (NYSE:CBM) opened at 46.75 on Friday. The stock has a market cap of $1.53 billion, a P/E ratio of 17.03 and a beta of 2.28. The company’s 50-day moving average price is $53.21 and its 200-day moving average price is $55.33. Cambrex Co. has a 12 month low of $38.30 and a 12 month high of $62.95.
Cambrex (NYSE:CBM) last released its quarterly earnings data on Friday, August 4th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.76. Cambrex had a net margin of 18.67% and a return on equity of 22.37%. The business had revenue of $134.55 million during the quarter, compared to analyst estimates of $136.82 million. During the same quarter in the previous year, the business earned $0.68 EPS. Cambrex’s quarterly revenue was up 13.4% compared to the same quarter last year. Equities analysts forecast that Cambrex Co. will post $3.08 earnings per share for the current year.
CBM has been the topic of several analyst reports. BidaskClub lowered Cambrex from a “hold” rating to a “sell” rating in a report on Thursday, August 24th. ValuEngine raised Cambrex from a “hold” rating to a “buy” rating in a report on Tuesday, August 22nd. Finally, Zacks Investment Research lowered Cambrex from a “buy” rating to a “hold” rating in a report on Tuesday, July 4th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $65.67.
In other news, CEO Steven M. Klosk sold 4,000 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $54.96, for a total transaction of $219,840.00. Following the completion of the transaction, the chief executive officer now owns 87,328 shares of the company’s stock, valued at $4,799,546.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Steven M. Klosk sold 12,000 shares of the company’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $51.53, for a total transaction of $618,360.00. Following the completion of the sale, the chief executive officer now directly owns 95,328 shares in the company, valued at approximately $4,912,251.84. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,000 shares of company stock valued at $1,574,880. 2.48% of the stock is owned by company insiders.
Cambrex Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Co. and related companies with MarketBeat.com's FREE daily email newsletter.